Oncology
ADCs, T-cell engagers, multi-specific antibodies
- Stages
- Preclinical to Phase 2+ and commercial
- Deal types
- Series A to growth, licensing, co-development, M&A
PXM expert assessment required
Life-science ventures & transactions · Europe | US
Science-led. Capital-ready. Deal-driven.
PXM is a life-science venture and transactions firm. Senior scientific, regulatory, clinical and CMC operators who source assets for investors and pharma, secure EU non-dilutive funding, join companies as part of their leadership, and lead licensing, partnering and M&A processes at every stage.
Former FDA reviewers on the expert panel
Every stage, from spinout to commercial
EU and US regulatory depth
Investment-committee-grade assessments
01
Four practices
One firm, from first look to closed transaction.
01
Scout
For pharma, corporate venture capital, VCs and family offices
We source and screen European and US assets against your thesis, from discovery to commercial stage. Every asset is assessed by our expert panel using the PXM Score.
Explore Scout 02Fund
For companies, startups, universities and tech-transfer offices
We build and lead EU non-dilutive funding applications end to end: EIC Accelerator (grant and equity), EIC Pathfinder and Transition, Horizon Europe health calls, IHI, Eurostars and national programs. Non-dilutive capital that extends runway and de-risks the asset before equity.
Explore Fund 03Operate
For companies and university spinouts
Senior PXM operators join your team as fractional heads of regulatory, CMC, clinical and business development, aligned through equity. We build the regulatory, CMC and evidence package investors and EU funders require.
Explore Operate 04Transact
For both sides
We lead licensing, co-development, partnering and M&A processes end to end, and prepare companies for financing including EU non-dilutive capital (EIC, Horizon Europe, IHI).
Explore Transact02
The PXM Score
Our diligence method.
Every asset is assessed by the PXM expert panel. Six dimensions expose the strengths, gaps and next milestones that determine investment, licensing and acquisition readiness at every stage.
Illustrative company
European Biologics Co.
82 / 100
Science88
Regulatory Pathway76
Clinical Strategy82
CMC & Manufacturability69
IP & Differentiation91
Market & Capital Fit79
03
How it works
Source. Fund. Build. Transact.
01
Source
We scout European and US assets against investor and pharma theses, from discovery to commercial stage.
02
Fund
We secure EU non-dilutive capital, from EIC Accelerator to Horizon Europe and IHI, that extends runway before equity.
03
Build
PXM operators join portfolio companies to close regulatory, CMC, clinical and evidence gaps.
04
Transact
We lead licensing, co-development, partnering, M&A and financing processes end to end.
04
Where we are scouting
Assets for investment, in-licensing and acquisition.
Discovery, preclinical, clinical and commercial-stage opportunities across Europe and the US, assessed for science, regulatory path, CMC and commercial potential before they reach your investment committee or BD team.
Immunology & Inflammation
Bispecifics, oral small molecules, autoimmune
- Stages
- Preclinical to Phase 2+ and commercial
- Deal types
- Series A to growth, licensing, co-development, M&A
PXM expert assessment required
Obesity & Cardiometabolic
Next-generation incretins, oral GLP-1, muscle-preserving therapies
- Stages
- Preclinical to Phase 2+ and commercial
- Deal types
- Series A to growth, licensing, co-development, M&A
PXM expert assessment required
Neurology & Rare Disease
Gene therapy, orphan drug designation candidates
- Stages
- Preclinical to Phase 2+ and commercial
- Deal types
- Series A to growth, licensing, co-development, M&A
PXM expert assessment required
Cell & Gene Therapy
In vivo CAR-T, allogeneic cell therapy, gene editing
- Stages
- Preclinical to Phase 2+ and commercial
- Deal types
- Series A to growth, licensing, co-development, M&A
PXM expert assessment required
Diagnostics, Medtech & AI Drug Discovery
Companion diagnostics, digital health, AI-enabled platforms
- Stages
- Preclinical to Phase 2+ and commercial
- Deal types
- Series A to growth, licensing, co-development, M&A
PXM expert assessment required
05
Team
Senior operators across every material risk.
06
Capital stack
Capital and strategic evidence across every stage.
01
Academic spinout · EU non dilutive
02
Seed · Angels & family offices
03
Series A/B/C · Venture capital
04
Clinical & growth · Growth funds and CVC
05
Commercial · Pharma partnerships, licensing & M&A
07
Sectors
Focused across the life science value chain.
Therapeutics · Biologics · Diagnostics · Medtech · Drug development enablers · Cardiometabolic.
08
Insights
Latest intelligence from PXM operators.
2026-10-05
What a Clinical Overview Must Contain for an EU Hybrid Application
What the Clinical Overview (Module 2.5) must cover in an EU hybrid application under Article 10(3), how to justify differences from the reference product, and where assessors push back.
2026-10-05
Well-Established Use Applications: Building a Bibliographic Clinical Overview That Holds Up
How to build the Clinical Overview for an EU well-established use application under Article 10a: the ten-year test, literature selection, and how to bridge your product to the published evidence.
2026-10-05
How to Choose an Independent Clinical Expert for Your EU Dossier
What Article 12 of Directive 2001/83/EC requires from the Clinical and Nonclinical Expert, what to look for when you appoint one, and the questions to ask before they sign.